



Cancer Immunotherapy in the COVID-19 Pandemic Era

Guest Editors:

**Dr. Amir Sasan Mozaffari
Nejad**

Dr. Mohammad Javad Mousavi

Dr. Mohsen Keshavarz

Deadline for manuscript
submissions:

closed (1 October 2024)

Message from the Guest Editors

The recent coronavirus disease-19 (COVID-19) pandemic, in addition to posing direct threats to health as well as economic and social pressures, has directly affected the management and treatment of other diseases. Among these, cancer immunotherapy regimens, as an effective method of treating different malignancies, have been affected by the widespread infections caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Patients treated through different immunotherapy routes have shown a range of responses, from recovery to severe forms of disease and even death due to COVID-19. However, in the wider context of immunotherapy, beyond those applied to cancer, different immunotherapies for the potential and actual treatment of infections have been proposed, especially during the recent pandemic.

This Special Issue aims to investigate the bilateral effects of the COVID-19 pandemic and the processes of different immunotherapies with respect to the aforementioned concerns.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com